Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

NCT04396860 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

159

Enrollment

NIH

Sponsor class

Conditions

Gliosarcoma
MGMT-Unmethylated Glioblastoma

Interventions

PROCEDURE: Contrast-enhanced Magnetic Resonance Imaging
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab
DEVICE: NovoTTF-100A Device
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
RADIATION: Radiation Therapy
DRUG: Temozolomide

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]